Study of Antigens in Drug-Resistant Lung Cancer Cells
Author Information
Author(s): S.E.L. Mirski, S.P.C. Cole
Primary Institution: Queen's University
Hypothesis
The antigens detected by monoclonal antibodies may serve as markers for non-P-glycoprotein-mediated mechanisms of resistance in small cell lung cancer.
Conclusion
The study identifies potential novel markers for drug resistance in small cell lung cancer, although their expression is often similar in both drug-sensitive and resistant cell lines.
Supporting Evidence
- The study found that the antigens detected by the antibodies are not overexpressed in all drug-resistant cell lines.
- Resistance-associated reactions were observed with some antibodies on specific cell lines, indicating potential markers for drug resistance.
- Immunoblotting showed that the proteins detected had similar molecular weights across different cell lines.
Takeaway
Researchers looked at proteins in lung cancer cells that resist drugs and found some that might help understand why these cells don't respond to treatment.
Methodology
The study involved using monoclonal antibodies to detect proteins in various drug-sensitive and resistant small cell lung cancer cell lines through immunoprecipitation and enzyme-linked immunosorbent assays.
Limitations
The antibodies did not distinguish all multidrug resistant cells from sensitive cells, indicating that multidrug resistance in this tumor type is heterogeneous.
Want to read the original?
Access the complete publication on the publisher's website